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Background:  Recently  Chikungunya  virus  (CHIKV)  outbreaks  have  been  reported  in  the  Carribean.  There
is no  data  regarding  the outbreak  in  Curac¸ ao. In  addition,  to  date  there  is  no  biomarker  that  could  be  used
to  predict  chronic  infection.
Objectives:  To  characterize  the  ﬁrst  CHIKV  outbreak  in  Curac¸ ao  and  to  identify  potential  biomarkers  for
chronic infection.
Study design:  A  serological  test  and  quantitative  polymerase  chain  reaction  (qPCR)  were  used on  samples
collected  in Curac¸ ao to conﬁrm  infection.  Subsequently,  six samples  with  high  viral  load  were  selected  for
phylogenetic  analysis.  Furthermore  we investigated  the  association  of  macrophage-related  biomarkers
during CHIKV  infection  with  chronic  arthralgia/arthritis.
Results: 116  patients  in  Curacao  were  diagnosed  with  CHIKV  infection  based  on  ELISA and  77% werehronic arthralgia tested  positive  for CHIKV  by  qPCR.  Phylogenetic  analysis  showed  that  an  Asian  genotype  was  the  cause  of
the  outbreak.  Elevated  levels  of  ferritin  and CRP  were  signiﬁcantly  associated  with  viraemia.  In  addition,
elevated  ferritin  levels  were  signiﬁcantly  associated  with  chronic  arthralgia.
Conclusions:  The  results  showed  that the  presence  of  an  Asian  genotype  of  CHIKV  in  Curac¸ ao  for  the  ﬁrst
time. Moreover,  we  found  an  association  between  ferritin  levels  with  chronic  arthralgia.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Background
Chikungunya virus (CHIKV) is an arthropod-borne alphavirus
hat cause dengue-like illness [1]. Three lineages of CHIKV
ave been identiﬁed to date, namely West African, Asian, and
ast-Central-South-Africa (ECSA) genotypes. In the past, CHIKV
utbreaks have only been reported occasionally in Africa and Asia.
n Asian lineage was introduced into the island of St Martin in 2013,
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/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
and quickly spread throughout the Caribbean, South and Central
America [2].
Between 20% and 50% of CHIKV-infected patients may  develop
chronic arthralgia. To date there is no marker that could be used
to predict chronic CHIKV infection. It is difﬁcult to predict who
will develop chronic disease and therefore ﬁnding biomarkers
associated with disease is an important step in understanding
pathogenesis and aiding the therapeutic decision-making to con-
trol the inﬂammation process early enough before any chronic
arthritis occurs.2. Objectives
Our aim was to describe the ﬁrst CHIKV outbreak on the Island
of Curac¸ ao, validate the commercially available diagnostic kits to
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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iagnose CHIKV infection, and identify markers associated with
hronic infection.
. Study design
.1. Validation of serology for diagnostics of the clinical samples
Samples were obtained from the unit of clinical virology at
he Department of Viroscience, Erasmus Medical Center. Fifty-two
erum pairs were selected from 26 travelers. To study cross-
eactivity of the serological assays, we selected sera from the same
erum bank of patients with other viral infections; 12 patients diag-
osed with an acute cytomegalovirus (CMV) infection, 17 patients
ith an acute Epstein-Barr virus (EBV) infection, three patients with
n acute Ross River virus (RRV) infection and 20 patients with an
cute DENV infection.
.2. Clinical samples from Curac¸ ao
Serum samples were collected during the 2014–2015 out-
reak at the Medical Laboratory Services (MLS) headquarter and
liquoted for RNA isolation and serology. A selection of patients
rom the MLS  database were selected for the retrospective study.
nly patients for which paired serum samples were available were
elected. Two groups were selected: 1) patients with laboratory
onﬁrmed CHIKV infection (based on ELISA) and 2) patients with
ther febrile illness (OFI). Febrile patients with a negative CHIKV
LISA in the acute and convalescent phase samples were diagnosed
s OFI.
.3. Chikungunya virus serology
CHIKV speciﬁc antibodies in sera from patients included in the
ohort from Curac¸ ao were determined using an IgM/IgG enzyme-
inked immunosorbent assay (ELISA) kit (IBL, Germany). In addition,
he IgM/IgG ELISA and the indirect immunoﬂuorescence assay
IFA) for IgM and IgG from Euroimmuun (Germany) were used
or comparison. All the assays were performed according to the
anufacturer’s protocol. The sero-status of all samples for the
alidation study was conﬁrmed in an in-house developed micro-
eutralization assay as previously described [3].
.4. Virus quantiﬁcation by real time-PCR
The detection and quantiﬁcation of CHIKV RNA in patient serum
as determined by qRT-PCR as previously described [4,5]. Viral
NA load was determined using a standard curve. CHIKV envelope
rotein 1 (E1) RNA run-off transcripts were used as a standard curve
nd were prepared as previously described for West Nile virus [6].
.5. Sequence and phylogenetic analyses of CHIKV genes
PCR reactions targeting a part of the E1, E2, and non-structural
rotein 2 (nsP2) were performed from samples of six patients with
ositive qRT-PCR results. Primers used for PCR and sequencing
ere derived from previous publications [7,8]. The phylogenetic
rees were constructed using 522 nucleotides of the E1 gene, 429
ucleotides of the E2 gene and 483 nucleotides of the nsP2 gene.
equences were aligned using MUSCLE software (v3.7) and the
hylogenetic trees were reconstructed using the maximum like-
ihood implemented in the PhyML software (v3.0). Both softwares
ere used from the website, http://phylogeny.lirmm.fr/as previ-
usly described [9].l Virology 86 (2017) 31–38
3.6. Levels of C-reactive protein, ferritin, anti-cyclic citrullinated
peptide antibody, rheumatoid factor and neopterin in serum
Serum C-reactive Protein (CRP), ferritin, anti-cyclic citrullinated
peptide (anti CCP) antibody and rheumatoid factor (RF) concentra-
tions were determined using a multi-channel Roche Cobas 6000
analyzer. The threshold/normal values for the biomarkers were
CRP (1 mg/dl), ferritin (man 30–400 ng/ml; woman 13–150 ng/ml),
anti CCP (17 U/ml), and RF (20 IU/ml). A group of 80 patients were
selected based on the ferritin serum levels for determination of
serum neopterin, anti CCP and RF levels. Neopterin levels were
measured using commercially available ELISA kit (IBL, Germany).
The assay was  performed according to the manufacturer’s instruc-
tion.
3.7. Patient questionnaire
All the patients that were selected to determine neopterin levels
were contacted and a questionnaire containing the following three
questions was  completed: 1) development of fever, 2) pain in the
muscle(s) or joint(s) and 3) appearance of rash. Subsequently the
patients were asked for how long after their visit to the general
practitioner the clinical symptoms persisted.
3.8. Statistical analysis
All statistical analyses were performed using GraphPad Prism
version 5.01 software (Graphpad Software, USA). For comparison
between continuous variables, Student’s t-test or Mann Whitney
test was  performed depending on the distribution of the data. Dif-
ferences in the proportion of patients were analysed by Chi-square
test or Fischer’s exact test depending on the normality of the data.
P values ≤ 0.05 were considered to be statistically signiﬁcant.
4. Results
4.1. Evaluation of diagnostic methods for detection of CHIKV
antibodies
First, a virus neutralization test (VNT) was  performed on 52
paired sera from 26 patients with suspicion of CHIKV infection. In 14
out of 26 patients (53.8%), neutralizing antibodies were detected in
the acute samples of the paired sera. In order to check if we possibly
missed early cases of infection by carrying out only neutralization
assay, we  additionally performed a CHIKV speciﬁc RT-PCR on all the
acute samples of the paired sera. We  detected CHIKV RNA in four
patients that did not have neutralizing antibodies and thereby we
conﬁrmed the diagnosis of CHIKV on the acute samples.
The commercially available ELISAs and IFA were compared with
the results of the VNT. The speciﬁcity of all the tests was above 90%
for IgM as well as IgG, indicating that the number of false-positive
results is very low. The sensitivity of all the tests was lower for both
IgM and IgG, varying from 84% to 92% (Table 1). Subsequently, we
analysed the cross-reactivity against RRV, EBV, CMC, and DENV of
the three commercial tests. All three assays showed the same IgM
cross-reactivity with RRV (33%) and different results were obtained
with sera from acute EBV infections (11.8–47.1%). In addition, the
Euroimmuun ELISA showed a large amount of cross-reactivity with
acute CMV  infection (41,7%), whereas the other two  assays did not
show cross-reaction (Table 2). In addition, the reproducibility of
the IFA is largely depending on the experience of the technician
performing the test (data not shown).
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Table  1
Performance of commercial serological methods versus virus neutralization test (VNT).
Euroimmuun IFA Euroimmuun ELISA Novatec ELISA
IgG IgM IgG IgM IgG IgM
pos neg pos neg pos neg pos neg pos neg pos neg
VNT
pos 22 3 23 2 21 4 23 2 22 3 23 2
neg  0 27 1 26 1 26 0 27 2 25 1 26
Sensitivity (%) 88 92 84 92 88 92
Speciﬁcity (%) 100 96.3 96.3 100 92.6 96.3
Data are depicted as number unless otherwise stated. Abbreviations: VNT: virus neutralization test; IFA: indirect immunoﬂuorescence assay; ELISA: enzyme-linked
immunosorbent assay; pos: positive; neg: negative.
Table 2
Cross reactivity of commercial serological assays for CHIKV.
VNT Euroimmuun IFA Euroimmuun ELISA Novatec ELISA Total no of patients (n)
IgG IgM IgG IgM IgG IgM
Acute CMV 0 0 0 0 41.7 0 0 12
Acute  EBV 0 0 11.8 0 47.1 5.9 23.5 17
Acute  RRV 0 67 33 0 33 0 33 3
Acute  DENV 0 0 0 0 10 15 5 20
D irus neutralization test; IFA: indirect immunoﬂuorescence assay; ELISA: enzyme-linked
i iver virus; DENV: dengue virus.
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Table 3
Comparison of clinical manifestations between high ferritin and normal ferritin
levels patients.
High ferritin levels
(n = 47)
Normal ferritin levels
(n = 25)
P
Fever 26 (55.3%) 12 (25%) 0.55
Rash 15 (31.9%) 8 (25%) 0.99
Joint(s)/muscle(s) pain 42 (89.4%) 7 (28%) <0.001
<3  months 3 (6.4%) 1 (4%) 0.67
≥3  months 39 (83%) 6 (24%) <0.001
CHIKV-infected patients were selected for neopterin ELISA. The
group of patients with elevated ferritin levels had signiﬁcantly
higher levels of neopterin (p = 0.03) compared to patients with nor-
mal  ferritin levels (Fig. 3).
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mmunosorbent assay; CMV: cytomegalovirus; EBV: Epstein-Barr virus; RR: Ross R
.2. CHIKV diagnostic results of the 2014–2015 outbreak in
urac¸ ao
In total 141 patients were included in the study. 116 patients
ere diagnosed with CHIKV infection based on the ELISA results.
iral RNA was  detected in 77% of the samples and the highest viral
NA load that was found in this study was 108 viral copies/ml blood.
n contrast, CHIKV RNA was not detected in any of the samples of
he OFI group (n = 25).
.3. Asian genotype in the outbreak in Curac¸ ao
The sequences from the Curac¸ ao viruses were obtained from the
1, E2 and nsP2 proteins (Fig. 1A–C). Sequences were deposited in
enBank under accession numbers KU727168-KU727181. Phylo-
enetic analyses of these partial sequences showed clustering of
he Curac¸ ao strains with the Asian Genotype. Closest relation of
he E1 Asian genotype isolates was seen with available genomes
rom the Americas outbreak (from Brazil, Mexico and St Martin).
hylogenetic analyses of the other proteins also showed clustering
f the isolates within the Asian genotype.
.4. Biomarkers associated with viraemia and chronic arthralgia
For an analysis of biomarkers in relation to viral load, we  ﬁrst
ivided the included patients in viraemic (qRT-PCR positive) and
on-viraemic (qRT-PCR negative) groups. As a negative control, we
sed serum samples from the OFI patients. We  further divided the
iraemic group in high viral load (VL) and low VL sub-groups based
n arbitrary copy numbers (≥104 copies were considered high and
104 copies low).
We found a signiﬁcant increase in ferritin serum level in
iraemic patients compared to non-viraemic patients (p = 0.0026)
nd patients with OFI (p = 0.0042) (Fig. 2A). In addition, the propor-
ion of patients with prolonged chronic arthralgia (≥3 months) was
igniﬁcantly higher in the group with high ferritin levels (p < 0.001)
ompared to normal ferritin levels (Table 3). CRP levels were sig-
iﬁcantly elevated in viraemic group compared to non-viraemic
p < 0.001) and OFI group (p < 0.001) (Fig. 2C). Furthermore, we
ound signiﬁcant differences in serum CRP levels when high VLData are no (%) of patients within the group, unless otherwise indicated. Patients
with elevated ferritin levels seem to have more chronic arthralgia (p < 0.001) which
last more than 3 months (p < 0.001) compared to patients with normal ferritin levels.
was compared with low VL (p = 0.0012) and OFI groups (p < 0.001)
(Fig. 2D).
To determine the neopterin levels, patients with normal or ele-
vated ferritin levels were selected from the cohort. In total 80Fig. 3. Correlation of serum neopterin levels with serum ferritin levels.
Serum neopterin levels in patients with elevated ferritin levels were signiﬁcantly
higher compared to the group with normal ferritin levels (p < 0.03). Horizontal red
lines indicate the median of the groups. Abbreviations: OFI: other febrile ilnessess.
*p  < 0.05; ** p < 0.01; *** p < 0.001.
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.5. Biomarkers associated with rheumatoid diseases
To conﬁrm whether the patients that experienced chronic
rthralgia/arthritis did not have rheumatoid diseases, we  measured
nti-CCP and RF serum levels. None of the CHIKV patients showed
levated serum levels for both anti-CCP and RF (data not shown).
hese results suggest that the chronic disease was caused by CHIKV
nfection.
. Discussion
This study reports the ﬁrst outbreak of CHIKV in Curac¸ ao, which
as caused by an Asian genotype. The ﬁrst CHIKV outbreak in the
aribbean was reported in late 2013 on the Island of St. Martin and
hortly thereafter more cases were reported on the other Caribbean
slands [2]. The ﬁrst suspected cases were detected approximately
ix months later in Curac¸ ao. Afterwards the virus quickly spread
hroughout Curac¸ ao. The majority of the patients described classic
HIKV symptoms (Table 3) [10].
Our study has several limitations. First, it is a retrospective study.
onsequently, owing to the risk of recall bias we could not assess
he whole spectrum of clinical symptoms. In addition, the cohort
f patients was relatively small, but sufﬁcient enough to justify the
onclusions.
ig. 1. Phylogenetic analyses of the CHIKV isolates. The sequences obtained in this study
ased  on the E1 gene. Panel B shows phylogenetic analysis of CHIKV isolates based on the
ene.  The CHIKV isolates from Curacao cluster with the strains isolated in the Americas an
CSA  = East Central South Africa. (For interpretation of the references to color in this ﬁgurl Virology 86 (2017) 31–38
The evaluation of the commercial assays was carried out to
ensure that the kit that was  used in Curac¸ ao is accurate and robust
to diagnose CHIKV infection. Our study showed that all the tests
evaluated had good sensitivity and speciﬁcity. The assays displayed
high speciﬁcity, which is important in a population with high pos-
itivity rates. Sensitivity was lower for the three ELISA kits, which
suggest an additional value of either PCR testing in the acute phase
or testing follow up (convalescent) sample [11]. It is also impor-
tant to always interpret the results of both IgM and IgG together,
which can increase the reliability of the diagnosis. IFA was also
tested in this study as several studies have shown that IFA tests
have good sensitivity and speciﬁcity [12,13]. However, the neces-
sity to have a well-equipped and adapted lab with experienced
staff, and high costs limit the use of this assay in daily clinical set-
tings [14]. Selection of the commercial kit should be made based
on the sensitivity and speciﬁcity of the assay and also no/low cross-
reactivity with other viruses. This is especially important for IgM,
which is an important parameter to diagnose acute infection. Our
study showed that all assays showed some degree of IgM cross-
reactivity against CMV  (Euroimmuun ELISA), EBV (all kits), and
DENV (Novatec and Euroimmuun ELISA). Cross-reactivity of the
commercially available ELISAs with other alphaviruses was also
shown previously [14]. These results imply that careful anam-
neses and physical examinations of patients in addition to other
 were marked with red dot. Panel A shows phylogenetic analysis of CHIKV isolates
 E2 gene. Panel C shows phylogenetic analysis of CHIKV isolates based on the nsP2
d other strains belonging to the Asian genotype. Abbreviations: WA = West Africa;
e legend, the reader is referred to the web version of this article.)
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iagnostic tools are important to obtain an accurate diagnosis in
elected cases.
Phylogenetic analyses of the CHIKV genes were in line with other
eports coming from the Americas. The fact that the CHIKV strain
irculating is closely related to the strains currently circulating in
he Americas suggests that the Curac¸ ao outbreak was a result of
n introduction of the virus from one of the neighboring Islands.
ecently a study reported the emergence of ECSA strain in Brazil
rom a patient that returned from Angola [15]. It has been shown
hat the A226V mutation in the viral E1 protein can increase viral
ransmission in A. albopictus,  which was associated with the large
HIKV epidemic in the Indian Ocean [16,17]. Given the presence of
. albopictus in many latin American countries and the extensive
ravelling between the islands in the region, there is a realistic risk
or introduction of the Indian Ocean sub-lineage in the future.inued)
We found signiﬁcantly elevated serum levels of CRP in CHIKV
patients with viraemia compared to non-viraemic and OFI groups.
C-reactive protein is an acute-phase protein that is synthesized by
the liver. Several studies showed that monocytes/macrophages and
hepatocytes are the target cell of CHIKV infection [18–20]. It has
been shown that CHIKV interactions with monocytes induced a
robust and rapid innate immune responses with the production
of cytokines and chemokines [18]. It is possible that hepatocytes
are indirectly activated by pro-inﬂammatory mediators and/or
activated immune cells to synthesize high amounts of CRP. Addi-
tionally, direct infection of hepatocytes could also initiate the
production of CRP. Our study is in line with previous studies that
also found increased CRP levels in patients infected with DENV,
another arbovirus, which also infects macrophages and hepato-
cytes [21,22].
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We  also found elevated serum levels of ferritin and neopterin,
hich are markers of activated marcophages. Studies have shown
hat synthesis of ferritin can be triggered by cytokines and iron
23,24]. In this study, increased concentrations of ferritin were
igniﬁcantly associated with viraemia. Macrophage and hepato-
yte are important producers of the secreted form of ferritin and
herefore direct infection and subsequent viral replication in these
ells may  activate them and increase the production of ferritin. We
lso found that a signiﬁcant number of patients with elevated fer-
itin levels in the acute serum sample developed chronic arthralgia.
yperferritinaemia has been shown to be associated with other
rboviral infections and autoimmune disorders like rheumatoid
rthritis (RA) and systemic lupus erythematosus (SLE) [25–27].
e did not ﬁnd positive rheumatoid markers (anti-CCP and RF) inur cohort, which suggest that elevated ferritin levels and chronic
rthralgia/arthritis were not caused by rheumatoid diseases. In this
tudy we also found an association between elevated ferritin lev-
ls with production of neopterin, which is a speciﬁc marker ofinued)
activated macrophages. Elevated serum levels of both molecules
were also shown to be associated with the severity of DENV infec-
tion [27,28]. The results presented in the manuscript support the
hypothesis that macrophages might play a role in the development
of chronic CHIKV infection. In addition, our results suggest that fer-
ritin could serve as a potential prognostic marker for development
of chronic CHIKV infection.
6. Conclusions
This study is the ﬁrst report of CHIKV emergence in Curac¸ ao.
We identiﬁed the etiological strain associated with the CHIKV out-
breaks in Curac¸ ao, which belongs to the Asian genotype. We  found
an association between hyperferritinaemia with chronic chikun-
gunya. Further studies are needed to evaluate whether ferritin
could serve as a potential prognostic markers for chronic chikun-
gunya.
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Fig. 2. Ferritin and C-reactive protein (CRP) serum levels in patients infected with CHIKV.
Samples selected in the Curacao 2014–2015 cohort were divided in qPCR positive (viraemic) and qPCR negative (non-viraemic) groups. (A) Ferritin serum levels were
signiﬁcantly elevated in viraemic patients compared to non-viraemic (p = 0.0026) and OFI group (p = 0.0042) (B) No signiﬁcant difference in ferritin levels was observed
between viraemic samples when divided into high VL and low VL (p = 0.929), indicating that the presence of viraemia rather than viral load determined the serum ferritin
levels.  (C) Serum CRP levels were signiﬁcantly increased in viraemic patientscompared to non-viraemic (p < 0.001) and OFI group (p < 0.001). CRP levels of patients classiﬁed
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an  high VL group was  signiﬁcantly elevated compared to low VL (p = 0.0012) and 
bbreviations: OFI: other febrile ilnessess; VL: viral load. *p < 0.05; ** p < 0.01; *** p
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